About: Novel adjuvants and vaccine delivery systems

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Novel adjuvants and vaccine delivery systems Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Novel adjuvants and vaccine delivery systems
Creator	Morein, Bror Bengtsson, Karin Sjblander, Anders Villacrks-Eriksson, Maria
source	Elsevier; Medline; PMC
abstract	Abstract Conventionally the efficiency of an adjuvant is measured by the capacity to induce enhanced antibody serum titres and cell mediated immunity (CMI) to a given antigen. Nowadays the capacity of an adjuvant is also measured by the quality as well as the magnitude of the induced immune response, guided by the protective immune response required. Quality includes isotype and IgG subclass responses, T-helper cell responses characterized by the cytokine profile and cytotoxic T cells (CTL). In the early phase of immunization some adjuvants influence the antigen administration and uptake by a so- called depot effect exemplified by aluminium hydroxide gel and oil adjuvants, which possibly is not as desired as alledged. A modern depot is exerted by slow release formulations continuously releasing the antigen over a period of time or by pulses at intervals aiming at ‘single injection’ vaccine. Great efforts are made to formulate efficient delivery formulations targeting the antigens from the site of administration, to draining lymph nodes or distant lymphatic tissue or to mucosal surfaces by parenteral or mucosal administrations. Nowadays, non-replicating carriers besides replicating vaccines are formulated to induce mucosal immune responses encompassing secretory IgA and CMI. Efforts to evoke immune responses on mucosal membranes distant from the site of administration have resulted mostly in little success. For a long time it was considered that CTL under the restriction of MHC Class I only could be evoked by replicating viruses or intracellular parasites. However, novel adjuvant delivery systems readily induce CTL by delivering the antigen to the APC resulting in intracellular transport to the cytosol for the MHC Class I presentation system, as well as to the endosomal pathway for the MHC Class II presentation.
has issue date	1996-11-30(xsd:dateTime)
bibo:doi	10.1016/s0165-2427(96)05697-8
bibo:pmid	8988882
has license	els-covid
sha1sum (hex)	c49595869663e8dff3487af03ed03d87efd3aa1d
schema:url	https://doi.org/10.1016/s0165-2427%2896%2905697-8
resource representing a document's title	Novel adjuvants and vaccine delivery systems
has PubMed Central identifier	PMC7119835
has PubMed identifier	8988882
schema:publication	Veterinary Immunology and Immunopathology
resource representing a document's body	covid:c49595869663e8dff3487af03ed03d87efd3aa1d#body_text
is schema:about of	named entity 'measured' named entity 'depot' named entity 'time' named entity 'antigens' named entity 'antigen' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software